<DOC>
	<DOCNO>NCT00061594</DOCNO>
	<brief_summary>This phase III , multicenter , randomize , double-masked , active treatment-controlled study intravitreally administer ranibizumab compare verteporfin ( Visudyne ) photodynamic therapy ( PDT ) treat subfoveal neovascular mascular degeneration .</brief_summary>
	<brief_title>A Study Compare rhuFab V2 With Verteporfin Photodynamic Treating Subfoveal Neovascular Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed informed consent Age &gt; =50 year Eligibility treatment PDT use verteporfin study eye accord Visudyne product label Future treatment PDT use verteporfin anticipate expect study eye Primary recurrent subfoveal choroidal neovascularization ( CNV ) lesion secondary agerelated macular degeneration ( AMD ) study eye A classic CNV component ( welldemarcated hyperfluorescence boundary early phase fluorescein angiogram ) &gt; =50 % total lesion size Total lesion size less equal 5400 um great linear dimension ( GLD ) Best correct visual acuity , use Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart , 20/40 20/320 ( Snellen equivalent ) study eye Prior treatment verteporfin , externalbeam radiation therapy , transpupillary thermotherapy ( TTT ) study eye Treatment verteporfin nonstudy eye le 7 day precede Day 0 Previous participation clinical trial ( either eye ) involve anti angiogenic drug ( pegaptanib , ranibizumab , anecortave acetate , protein kinase C inhibitor , etc . ) Previous intravitreal drug delivery ( e.g. , intravitreal corticosteroid injection device implantation ) study eye Previous subfoveal focal laser photocoagulation study eye Laser photocoagulation ( juxtafoveal extrafoveal ) study eye within 1 month precede Day 0 History vitrectomy surgery study eye History submacular surgery surgical intervention AMD study eye Previous participation study investigational drug within 1 month precede Day 0 ( exclude vitamin mineral ) Subretinal hemorrhage study eye involve center fovea , size hemorrhage either &gt; =50 % total lesion area &gt; =1 disc area ( DA ) size Subfoveal fibrosis atrophy study eye CNV either eye due cause , ocular histoplasmosis , trauma , pathologic myopia Retinal pigment epithelial tear involve macula study eye Any concurrent intraocular condition study eye ( e.g. , cataract diabetic retinopathy ) , opinion Investigator could either : ( 1 ) Require medical surgical intervention 24month study period prevent treat visual loss might result condition , ( 2 ) If allow progress untreated , could likely contribute loss least 2 Snellen equivalent line best correct visual acuity 24month study period Active intraocular inflammation ( grade trace ) study eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye History idiopathic autoimmuneassociated uveitis either eye Infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Aphakia absence posterior capsule study eye Spherical equivalent refractive error study eye demonstrate 8 diopter myopia Intraocular surgery ( include cataract surgery ) study eye within 2 month precede Day 0 Uncontrolled glaucoma study eye ( defined intraocular pressure &gt; =30 mmHg despite treatment antiglaucoma medication ) History glaucoma filter surgery study eye History corneal transplant study eye Premenopausal woman use adequate contraception History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Current treatment active systemic infection History allergy fluorescein , amenable treatment Inability obtain fundus photograph fluorescein angiograms sufficient quality analyze graded central reading center Inability comply study follow procedure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Neovascular age-related macular degeneration</keyword>
</DOC>